Drug Trial Radar · NCT05813678
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
Last checked: Nov 20, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Jun 6, 2022
Primary completion
Nov 1, 2033
Study completion Nov 1, 2033
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Apr 14, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 10-year multi-center, global, observational study to further characterize the safety profile of pegvaliase, including hypersensitivity reactions, long-term safety and tolerability, and the effectiveness of the additional risk minimization measures (aRMMs) (European Union (EU) only) in subjects receiving pegvaliase for the treatment of PKU. Subjects for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment (incident-users) or have previously started treatment with pegvaliase at the date of enrollment (prevalent-users) are eligible for participation in this study.
Conditions
- Phenylketonuria (PKU)
Interventions
PegvaliaseDrug
This is an uncontrolled, single-cohort, Phase 4 observational study not falling under the definition of an Applicable Clinical Trial (ACT) (i.e., non-interventional).
Primary outcomes
What the sponsor says the trial is designed to measure.
- To quantify and characterize the risk of protocol-defined safety events in incident-users receiving pegvaliase for the treatment of PKU in a real¬ world setting.Time frame: A maximum of 10 years treatment duration.
Locations
26 sites in 3 countries. Site status is shown where the registry gives one.
University of Colorado
Aurora, Colorado · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
Indiana University School of Medicine
Indianapolis, Indiana · Recruiting
Tulane University Medical Center
New Orleans, Louisiana · Recruiting
Boston Children's Hospital
Boston, Massachusetts · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Recruiting
Vanderbilt University Medical School
Nashville, Tennessee · Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Hospital Carl-Thiem-Klinikum Cottbus
Cottbus, Germany · Recruiting
Universitaetsklinikum Hamburg Eppendorf
Hamburg, Germany · Recruiting
Universitaetslinikum Leipzig AoeR
Leipzig, Germany · Recruiting
Johannes Gutenberg University of Mainz
Mainz, Germany · Recruiting
Universitätsklinikum Münster (UKM)-Pädiatrische Universitätsklinik Münster
Münster, Germany · Recruiting
Universität Ulm
Ulm, Germany · Recruiting
Policlinico Sant'orsola Malpighi
Bologna, Italy · Recruiting
University Hospital Careggi
Florence, Italy · Recruiting
Ospedale San Paolo
Milan, Italy · Recruiting
Azienda Ospedaliera Universitaria "Federico II" Dipartimento di Pediatria
Naples, Italy · Recruiting
Azienda Ospedaliera di Padova
Padova, Italy · Recruiting
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Palermo, Italy · Recruiting
Policlinico Gemelli
Rome, Italy · Recruiting
Sapienza University of Rome Hospital
Rome, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.